Tivoxavir marboxil (TXM) — Regulatory decision
Late 2026
The Company is preparing a comprehensive response to address the FDA's concerns, with the goal of resolving the hold and advancing the program in the US by the end of 2026.Source filing
TRAW biotech catalysts & pipeline
TRAWS PHARMA INC · Data as of 2026-10-25